Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study

被引:26
作者
Younes, Ramy [1 ]
Rosso, Chiara [1 ]
Petta, Salvatore [2 ]
Cucco, Monica [1 ]
Marietti, Milena [1 ]
Caviglia, Gian Paolo [1 ]
Ciancio, Alessia [1 ]
Abate, Maria Lorena [1 ]
Camma, Carlo [2 ]
Smedile, Antonina [1 ]
Craxi, Antonio [2 ]
Saracco, Giorgio Maria [1 ]
Bugianesi, Elisabetta [1 ]
机构
[1] Univ Torino, Dept Med Sci, Div Gastroenterol & Hepatol, Turin, Italy
[2] Univ Palermo, Sez Gastroenterol, DiBiMIS, Palermo, Italy
关键词
fibrosis; non-invasive marker; steatohepatitis; TRANSIENT ELASTOGRAPHY; STIFFNESS MEASUREMENT; PLASMA CYTOKERATIN-18; SCORING SYSTEM; FIBROSIS; DISEASE; NAFLD; RELIABILITY; PERFORMANCE; PROGRESSION;
D O I
10.1111/liv.13612
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & AimsThe non-invasive identification of steatohepatitis (NASH) in patients with Non-Alcoholic Fatty Liver Disease is an unmet need in clinical practice. Index of NASH (ION) is a new tool for the prediction of NASH. We aimed to externally validate ION and to compare it with CK-18. Since necroinflammation precedes fibrosis, we also tested ION in combination with non-invasive tools for fibrosis. MethodsWe analysed data from 292 Italian patients (169 Southern cohort, and 123 Northern cohort) with an histological diagnosis of NAFLD. The ION, FIB-4 and NFS scores were calculated according to published algorithms. Serum cytokeratin18-Aspartate396 levels and liver stiffness (LS) by Fibroscan were assessed within three months from liver biopsy. ResultsThe diagnostic accuracy of ION for the identification of NASH was not as satisfactory as reported (area under the ROC curve, AUROC=0.687 [95% CI=0.62-0.75]). The proposed cut-off value 50 showed a poor sensitivity (Se) (28%) and a good specificity (Sp) (92%), with a positive predictive value (PPV) of 91% and a negative predictive value (NPV) of 30%. A new cut-off value >26 improved Se (73%) but decreased Sp (60%) (PPV of 84% and a NPV of 43%). ION performed slightly better in obese NAFLD (AUROC=0.700). The combination of ION and markers of fibrosis did not improve the identification of advanced liver disease. ConclusionsION is not feasible for the non-invasive diagnosis of NASH across different populations of NAFLD patients, mainly because its limited reproducibility in non-obese subjects.
引用
收藏
页码:715 / 723
页数:9
相关论文
共 26 条
[1]   The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD [J].
Angulo, Paul ;
Hui, Jason M. ;
Marchesini, Giulio ;
Bugianesi, Ellisabetta ;
George, Jacob ;
Farrell, Geoffrey C. ;
Enders, Felicity ;
Saksena, Sushma ;
Burt, Alastair D. ;
Bida, John P. ;
Lindor, Keith ;
Sanderson, Schuyler O. ;
Lenzi, Marco ;
Adams, Leon A. ;
Kench, James ;
Therneau, Terry M. ;
Day, Christopher P. .
HEPATOLOGY, 2007, 45 (04) :846-854
[2]   Long-Term Mortality in Nonalcoholic Fatty Liver Disease: Is Liver Histology of Any Prognostic Significance? [J].
Angulo, Paul .
HEPATOLOGY, 2010, 51 (02) :373-375
[3]   Utility and Appropriateness of the Fatty Liver Inhibition of Progression (FLIP) Algorithm and Steatosis, Activity, and Fibrosis (SAF) Score in the Evaluation of Biopsies of Nonalcoholic Fatty Liver Disease [J].
Bedossa, Pierre .
HEPATOLOGY, 2014, 60 (02) :565-575
[4]   Comparison of blood tests for liver fibrosis specific or not to NAFLD [J].
Cales, Paul ;
Laine, Fabrice ;
Boursier, Jerome ;
Deugnier, Yves ;
Moal, Valerie ;
Oberti, Frederic ;
Hunault, Gilles ;
Rousselet, Marie Christine ;
Hubert, Isabelle ;
Laafi, Jihane ;
Ducluzeaux, Pierre Henri ;
Lunel, Francoise .
JOURNAL OF HEPATOLOGY, 2009, 50 (01) :165-173
[5]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[6]   Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease [J].
Cusi, Kenneth ;
Chang, Zhi ;
Harrison, Steve ;
Lomonaco, Romina ;
Bril, Fernando ;
Orsak, Beverly ;
Ortiz-Lopez, Carolina ;
Hecht, Joan ;
Feldstein, Ariel E. ;
Webb, Amy ;
Louden, Christopher ;
Goros, Martin ;
Tio, Fermin .
JOURNAL OF HEPATOLOGY, 2014, 60 (01) :167-174
[7]   EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease [J].
European Association for the Study of the Liver .
DIABETOLOGIA, 2016, 59 (06) :1121-1140
[8]   Cytokeratin-18 Fragment Levels as Noninvasive Biomarkers for Nonalcoholic Steatohepatitis: A Multicenter Validation Study [J].
Feldstein, Ariel E. ;
Wieckowska, Anna ;
Lopez, A. Rocio ;
Liu, Yao-Chang ;
Zein, Nizar N. ;
McCullough, Arthur J. .
HEPATOLOGY, 2009, 50 (04) :1072-1078
[9]  
FerroLuzzi A, 1995, WHO TECH REP SER, V854, P1
[10]   Performance of transient elastography for the staging of liver fibrosis: A meta-analysis [J].
Friedrich-Rust, Mireen ;
Ong, Mei-Fang ;
Martens, Swantje ;
Sarrazin, Christoph ;
Bojunga, Joerg ;
Zeuzem, Stefan ;
Herrmann, Eva .
GASTROENTEROLOGY, 2008, 134 (04) :960-974